Results 91 to 100 of about 8,127 (167)

Ribociclib Extends Survival in HR+ Breast Cancer

, 2018
Adding the CDK4/6 inhibitor ribociclib to standard first-line endocrine therapy significantly prolonged survival in premenopausal and perimenopausal women with advanced HR-positive, HER2-negative breast cancer enrolled in the MONALEESA-7 trial.

core   +1 more source

New Therapeutic Scenarios in the Context of Adjuvant Treatment for HR+/HER2−Breast Cancer: The Possible Role of Ribociclib in Treatment Algorithms for Stage II and III

Current Oncology
Early breast cancer (EBC) treatment has evolved from radical surgery to a multidisciplinary approach, integrating radiotherapy, chemotherapy, targeted therapy, and hormone therapy with surgery to ensure the best possible outcome.
Nicola Battelli, Carmela Mocerino, Michele Montedoro, Mirco Pistelli, Ilaria Portarena, Mario Rosanova, Tina Sidoni, Patrizia Vici   +7 more
doaj   +1 more source

Το Ribociclib ως νέα θεραπευτική προσέγγιση για τον καρκίνο του μαστού: μηχανισμοί, αποτελεσματικότητα και μελλοντικές προοπτικές [PDF]

Εισαγωγή: Ο καρκίνος του μαστού αποτελεί μια από τις συχνότερες κακοήθειες παγκοσμίως. Οι αναστολείς CDK4/6, όπως το ribociclib, έχουν αναδειχθεί ως μια σημαντική θεραπευτική επιλογή για ασθενείς με ορμονοθετικό, HER2-αρνητικό καρκίνο του μαστού.
Markellou Sotiria, Μαρκέλλου Σωτηρία   +1 more
core   +1 more source

Initial ribociclib plus endocrine therapy for HR+/HER2− advanced breast cancer in pre‐ and postmenopausal Chinese women: Primary results from a phase 2 randomized study

Cancer Medicine
Background The MONALEESA‐7 and ‐2 phase 3 randomized trials demonstrated a statistically significant progression‐free survival (PFS) and overall survival (OS) benefit with initial ribociclib + endocrine therapy (ET) versus placebo + ET in pre‐ and ...
Zhimin Shao, Zhongsheng Tong, Qiang Liu, Wei Li, Li Cai, Kunwei Shen, Huiping Li, Chuan Wang, Jin Yang, Zhenchuan Song, Shui Wang, Ting Luo, Wenhe Zhao, Haibo Wang, Yueyin Pan, Jianyun Nie, Xiaohua Zeng, Yanqing Bai, Wendy Chiang, Valeria Guarnaccia, Yu Bi, Binghe Xu   +21 more
doaj   +1 more source

Cost-Effectiveness of Adjuvant Abemaciclib and Ribociclib in High-Risk Hormone Receptor–Positive Early Breast Cancer: An Indian Perspective

JCO Global Oncology
PURPOSEIncorporating adjuvant cyclin-dependent kinase (CDK) 4/6 inhibitors abemaciclib and ribociclib along with endocrine therapy has been shown to improve invasive disease-free survival (iDFS) for hormone receptor–positive (HR+) human epidermal ...
Manraj Singh Sra, Archana Sasi, Atul Batra, Sameer Bakhshi, Shuvadeep Ganguly   +4 more
doaj   +1 more source

Risk factors of hepatotoxicity with ribociclib in hormone receptor-positive breast cancer

Background: The standard first-line treatment for hormone receptor-positive metastatic breast cancer is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, including palbociclib, ribociclib, or abemaciclib, combined
Chia-Chen Hsu, Sheng-Fan Wang, Wei-Chi Lin, Ling-Ming Tseng, Chian-Ying Chou, Yu-Li Chang, Ta-Chung Chao   +6 more
core   +1 more source

Matching-adjusted indirect comparison of ribociclib + nonsteroidal aromatase inhibitor versus abemaciclib + endocrine therapy in hormone receptor-positive/HER2-negative early breast cancer

Journal of Comparative Effectiveness Research
Aim: Ribociclib + nonsteroidal aromatase inhibitor (NSAI) and abemaciclib + endocrine therapy (ET) are approved for high-risk hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer based on data from
Stephen Chia, Jie Li, Fei Ma, Daniel Stellato, Andriy Danyliv, Ilia Ferrusi, Huilin Hu, Murat Akdere, Andreas Makris   +8 more
doaj   +1 more source

Plasma 4β-Hydroxycholesterol Predicts Ribociclib CYP3A-Mediated Metabolism, but Not Plasma Exposure, in Patients with Primary Brain Cancer. [PDF]

Cancers (Basel)
Wickramasinghe C, Bao X, Jiang Y, Jiang J, Yue Y, Sanai N, Li J.   +6 more
europepmc   +1 more source

Economic value of ribociclib in early breast cancer in the United States. [PDF]

J Manag Care Spec Pharm
Brufsky A, Tolaney SM, Gadi VK, Chai X, Yang F, Chen W, Ma W, Zhou ZY, Ganapathy V, Patel A, Sopher G, Alexander E, Bollu V, Garrison LP, Sparano JA.   +14 more
europepmc   +1 more source

Rationale and trial design of RIBOLARIS: A phase II trial of neoadjuvant and adjuvant ribociclib plus endocrine therapy for clinically high-risk HR+/HER2-negative breast cancer. [PDF]

Ther Adv Med Oncol
Cottu P, Pascual T, Lemonnier J, Hu H, Roux E, Connolly RM, Ma CX, Wolff AC, Crestani T, Tolosa P, Ferrero-Cafiero JM, Mulero-Sánchez A, Salvador F, Villacampa G, Gavilá J, de La Motte Rouge T, Prat A.   +16 more
europepmc   +1 more source